Immuneel Therapeutics Private Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Immuneel Therapeutics Private Limited - overview
Established
2018
Location
Bangalore, Karnataka, India
Primary Industry
Biotechnology
About
Based in India and founded in 2018, Immuneel Therapeutics Private Limited, operates as a biotech company, providing cell therapy and personalized immunotherapy for cancer patients. The company was founded by Biocon founder and chairperson Kiran Mazumdar-Shaw, Dr. Siddhartha Mukherjee, U. S.
oncologist and author of the Pulitzer Prize-winning novel, and Kush Parmar. Immuneel Therapeutics offers access to Chimeric Antigen Receptor T cell therapy (CAR-T), name named IMAGINE, and other cellular immunotherapies for the management and treatment of cancers. Immuneel’s IMAGINE trial for CD19 CAR-T (IMN-003A) for B cell malignancies (Leukemia & Lymphoma) is ongoing in India. Immuneel has exclusive rights to ARI-0001/IMN-003A (a CD-19 CAR-T cell therapy) from Hospital Clínic de Barcelona and Institut d’Investigacions Biomèdiques August Pi i Sunyer in Spain to develop, manufacture and commercialize in India via technology transfer.
In June 2026, Immuneel Therapeutics Private Limited raised INR 1 billion in series B funding from Singularity AMC and Rainmatter, with participation from Eight Roads Ventures and F-Prime Capital.
Current Investors
F-Prime Capital, Eight Roads Ventures, True North
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.immuneel.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Immuneel Therapeutics Private Limited - timeline of key events
Immuneel Therapeutics Private Limited - financials
| Fiscal Year Ended | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 |
|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - |
| EBITDA (USD) | (1,806,457) | (54,581,250) | - | - | - |
| Operating Income (USD) | (1,806,457) | (54,646,536) | - | - | - |
| Operating Margin | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - |
| NET Income (USD) | (1,806,457) | (47,958,864) | - | - | - |
| % Net Margin | - | - | - | - | - |
Immuneel Therapeutics Private Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.